Ebola Treatment Tips: US Government Supports Development of Opaganib

The United States government is supply support for the development of a new treatment for the deadly Ebola virus by RedHill Biopharma, an Israeli firm. The support is being impart through the Biomedical Advanced Research and Development Authority ( BARDA ), which is part of the US Department of Health and Human Services Administration for Strategic Preparedness and Response ( ASPR).

stopping_point year, a survey conduct by RedHill show that the opaganib medicine, given in twice-daily oral dose, increase the survival rate of mouse infect with Ebola from six days to 11 days. Opaganib is a host-direct therapy, which means it make an environment that is less conducive for the virus to boom rather than directly attack the pathogen.

In addition to its potential as a treatment for Ebola, opaganib is also being develop as a therapy for assorted cancer, COVID-19, and other viral and inflammatory disease. RedHill's Chief Business Officer, Guy Goldberg, foreground the pressing need for effective treatment for Ebola, as the virus is extremely deadly, with an average fatality rate of 50%.

It has been a decade since the lay_waste_to West Africa Ebola epidemic that claim the life of 11,000 people, yet there are still no approve host-direct small molecule therapy for the virus. Currently, the lone FDA-approve treatment for Ebola are Inmazeb, a combination of three monoclonal_antibody antibody, and Ebanga, a single monoclonal_antibody antibody. Goldberg stress the necessity for extra easy-to-distribute and administer therapy for Ebola to address this critical checkup need.

given the urgency and badness of the Ebola virus, the development of new treatment like opaganib is crucial in better survival rates and supply more effective scheme for battle the disease. The collaboration between RedHill Biopharma and the US government through BARDA clasp promise for advance research and development in the battle against Ebola and other infectious diseases.